Work

Efficacy and safety of second-line therapy with serplulimab, lenvatinib, and paclitaxel in patients with gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) for whom immunochemotherapy failed: A multicenter, single-arm, phase II trial (STILL).

Year: 2025

Type: conference-abstract

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e16075

Authors: Song Li, Li Meng, Haiyan Liu, Shifeng Kan, Lei Cong, Zhen Li, Zimin Liu, Xiaomei Xu, Wenfei Han, Jian Wang, Yunxia Chu, Cuihua Yi, Lian Liu

Institutions: Shandong University, Qilu Hospital of Shandong University, Qingdao University, Taian City Central Hospital, Shandong First Medical University, Zaozhuang Municipal Hospital, Shandong Provincial Hospital, Affiliated Hospital of Qingdao University, Qingdao Municipal Hospital

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410810629

Cites:

Cited by:

Related to: 10